<DOC>
	<DOCNO>NCT01377844</DOCNO>
	<brief_summary>The purpose study evaluate efficacy EGT0001442 lowering glycosylated Hemoglobin ( HbA1c , A laboratory test diagnose three month average blood sugar ) level 24th week baseline , compare placebo group ( diabetic medication give ) . The secondary aim study evaluate efficacy EGT0001442 lower fast blood glucose week 2 24 comparing result placebo group . This study ass efficacy EGT0001442 base proportion subject reach American Diabetes Association ( ADA ) target HbA1c &lt; 7 % EGT0001442 group comparison placebo . The study also evaluate effect EGT0001442 systolic , diastolic pressure , body weight compare respective placebo groups.This study also assess change baseline HbA1c overtime , week 1 week 96 . Finally , assess safety EGT0001442 Type 2 Diabetic patient ( adult/maturity onset ) .</brief_summary>
	<brief_title>Efficacy Safety EGT0001442 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>EGT0001442 compound may inhibit effect compound body know sugar transporter . The use EGT0001442 may enhance elimination glucose blood increase amount urine produce . Hence blood glucose level significantly decrease efficacy EGT001442 establish assess three month average blood glucose level ( HbA1c ) . Due increase urinary output , effect EGT001442 blood pressure level also assess .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject ≥18 year old Diagnosed type 2 diabetes Body mass index ( BMI ) ≤ 45 kg/m2 HbA1c 7 10 % ( inclusive ) screen FPG &lt; 250 mg/dL screen subject treat oral antidiabetic therapy FPG &lt; 240 mg/dL screen subject treat antidiabetic therapy Diabetes currently treat diet exercise diet exercise along one approve oral antidiabetic agent If take antidiabetic medication , dose regimen must stable past 3 month If take antihypertensive medication , dose regimen must stable past 3 month If take lipid modifying therapy , dose regimen must stable past 3 month Blood glucose &lt; 250 mg/dL base finger stick blood glucose subject randomization Hemoglobinopathy affect HbA1c measurement Current use inject therapy treatment diabetes ( insulin GLP1 receptor base therapy ) Genitourinary tract infection within 6 week screen Greater 2 episode genitourinary tract infection past year History kidney stone , bladder malfunction significant risk factor urinary tract infection eGFR , calculated modification diet renal disease study equation ( MDRD ) , &lt; 50 mL/min/1.73 m2 Abnormal test liver function ALT , AST bilirubin ≥ 3x ULN Diagnosis retinopathy significant nephropathy ( eGFR &lt; 50 mL/min/1.73 m2 Uncontrolled hypertension ( systolic blood pressure &gt; 160 diastolic blood pressure &gt; 95 ) Not willing use effective birth control , female childbearing potential Life expectancy &lt; 2 year New York Heart Association ( NYHA ) Class 4 heart failure Sera positive HCV , HIV , positive drug screen Currently participate another interventional trial Previous treatment EGT0001442 EGT0001474 Not able comply study schedule visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes mellitus</keyword>
</DOC>